Lyndra Therapeutics and Gilead Sciences to collaborate on development of ultra-long-acting HIV therapeutics

This article was originally published here

Gilead will have exclusive rights to Lyndra’s therapeutics platform for ultra-long-acting formulations related to HIV. Lyndra’s ultra-long-acting dosage form has the potential to improve medication adherence by allowing

The post Lyndra Therapeutics and Gilead Sciences to collaborate on development of ultra-long-acting HIV therapeutics appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply